Valentina Incardona

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
AIMS The pivotal ATLANTA first-in-man study showed the promising safety and efficacy profile of the novel Catania™ stent in a population with ~20% American College of Cardiology/American Heart Association (ACC/AHA) type C coronary lesions. The ATLANTA 2 registry was designed to evaluate the 12-month safety and efficacy of the Catania stent in a broader real(More)
  • 1